CAPLYTA Drug Patent Profile

When do Caplyta patents expire, and what generic alternatives are available?

Caplyta is a drug marketed by Intra-cellular and is included in one NDA. There are twenty-five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-eight patent family members in twenty countries.

The generic ingredient in CAPLYTA is lumateperone tosylate. One supplier is listed for this compound. Additional details are available on the lumateperone tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Caplyta

Caplyta was eligible for patent challenges on December 20, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 10, 2040. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (lumateperone tosylate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for CAPLYTA

International Patents:	178
US Patents:	25
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	3
Drug Prices:	Drug price information for CAPLYTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CAPLYTA
What excipients (inactive ingredients) are in CAPLYTA?	CAPLYTA excipients list
DailyMed Link:	CAPLYTA at DailyMed

See drug prices for CAPLYTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CAPLYTA

Constraining patent/regulatory exclusivity:

12,410,195

NDA:

209500

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CAPLYTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Intra-Cellular Therapies, Inc.	Phase 4
University of Massachusetts, Worcester	Phase 4
University of New Mexico	Phase 4

See all CAPLYTA clinical trials

Pharmacology for CAPLYTA

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for CAPLYTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CAPLYTA	Capsules	lumateperone tosylate	42 mg	209500	7	2023-12-20

US Patents and Regulatory Information for CAPLYTA

CAPLYTA is protected by forty-one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 12,410,195.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	11,690,842		Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	10,464,938		Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	11,026,951
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes	8,648,077		Y	Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	8,648,077		Y	Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No	12,410,195		Y

Expired US Patents for CAPLYTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019	7,183,282
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019	RE39680

International Patents for CAPLYTA

When does loss-of-exclusivity occur for CAPLYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAPLYTA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009145900
Japan	2021535151	新規方法
World Intellectual Property Organization (WIPO)	0077010
Russian Federation	2682658	НОВЫЕ СПОСОБЫ (NEW METHODS)
European Patent Office	3843739	NOUVELLES MÉTHODES (NOVEL METHODS)
Israel	280913	שיטות חדשות (Novel methods)
Mexico	2016007219	METODOS NOVEDOSOS. (NOVEL METHODS.)

Market Dynamics and Financial Trajectory of CAPLYTA (Lumateperone)

Last updated: February 19, 2026

CAPLYTA (lumateperone) is an atypical antipsychotic marketed by Sunovion Pharmaceuticals, approved initially by the FDA in December 2019 for schizophrenia in adults and later for bipolar depression in adults in August 2021. Its market performance and financial outlook are driven by patent protection, competitive landscape, regulatory developments, and evolving prescribing patterns.

---

Market Size and Growth Drivers

Addressable Markets

Segment	Market Value (USD billion)	Key Factors
Schizophrenia (global)	$14.4 (2022 projected)	Rising prevalence, aging populations
Bipolar disorder (global)	$6.8 (2022 projected)	Increased diagnosis, unmet needs

Sources: IQVIA, GlobalData

Growth Drivers

1. Rising Prevalence: Increasing cases of schizophrenia and bipolar disorder bolster demand.
2. Limited Treatment Options: CAPLYTA's novel mechanism targets unmet needs.
3. Orphan Drug Status: Potential for premium pricing due to limited options.
4. Expanding Indications: Possible future approvals for additional psychiatric conditions.

---

Competitive Landscape

Key Players	Market Share (2022)	Strengths	Weaknesses
Eli Lilly (Zyprexa, Abilify)	35%	Well-established, extensive clinical data	Side effect profiles, patent expirations
Otsuka (Abilify)	20%	Broad labeling, global reach	Competition from newer drugs
Sunovion (Caplyta)	5%	Novel mechanism, first-in-class approval	Limited market share, brand recognition
Others	40%	Diversified portfolios	Smaller market presence

Note: Caplyta holds a niche market share, with growth tied to new indications and uptake.

---

Regulatory and Patent Status

• Initial Approval: December 2019 (FDA, schizophrenia)
• Additional Approval: August 2021 (FDA, bipolar depression)
• Patent Expiration: Expected in 2030, with potential for extensions via orphan drug designation or formulation patents.
• Market Exclusivity: Until at least 2030, barring generic entry.

---

Financial Trajectory

Revenue Trends

Year	Estimated Revenue (USD million)	Notes
2020	$50	Launch year, modest uptake
2021	$150	Growth due to broader indication approvals
2022	$300	Rapid expansion in prescriber base
2023	$500 (projected)	Continued market penetration

Price and Pricing Strategy

• Wholesale Acquisition Cost (WAC): Approximately $800 per month per patient (2022)
• Pricing Strategy: Premium pricing attributed to novel mechanism; possible discounts for insurers and part of value-based agreements.

Cost Structure and Profitability

• High R&D costs absorbed prior to approval.
• Cost of goods sold (COGS): Estimated at 10-15% of revenue.
• Margins: Gross margins expected at 60-65%.

Future Revenue Drivers

• Expansion into additional indications such as agitation in dementia.
• Increased market penetration through physician acceptance.
• Potential partnership or licensing deals in international markets.

---

Market Risks and Opportunities

Risks

• Generic Competition: Entry anticipated post-patent expiry, affecting revenue.
• Regulatory Challenges: Additional indications require successful trials.
• Market Penetration: Prescriber adoption rate critical for growth.

Opportunities

• Label Expansion: Broader psychiatric or neurological indications.
• Partnerships: Licensing with regional distributors.
• Innovation: Development of formulations reducing side effects.

---

Summary and Outlook

CAPLYTA has experienced steady growth since its launch, fueled by its unique pharmacology, expanding indications, and a relatively limited competitive footprint. Revenue growth is expected to accelerate through new approvals and increased prescriber acceptance, contingent on market penetration and pricing strategies. Patent protection secures market exclusivity until at least 2030, providing a window for sustained revenue generation. Risks remain from generic competition and regulatory hurdles; strategic measures—such as indication expansion and international rollout—are essential to maximize the drug’s financial impact.

---

Key Takeaways

• CAPLYTA's initial revenues reflect niche positioning, with strong growth potential.
• The pharmaceutical's market share remains limited but is poised to increase with ongoing approvals.
• Patent exclusivity extends into the late 2020s, safeguarding against generic competition for now.
• Revenue acceleration depends on prescriber adoption and successful indication expansion.
• Competitive pressures may influence future pricing and profitability margins.

---

FAQs

1. When is CAPLYTA patent expiration expected?
Patent rights are expected to extend until 2030, with possible extensions through supplementary patents or orphan drug designation.

2. What are the main competitors to CAPLYTA?
Zyprexa and Abilify by Eli Lilly, both with large market shares and established prescriber base.

3. How does CAPLYTA's pricing compare to other antipsychotics?
It is priced at a premium, approximately $800 per month per patient, reflecting its novel mechanism.

4. Are there plans for additional indications?
Yes, ongoing trials aim to expand to other psychiatric conditions, potentially boosting revenue.

5. What factors could hinder CAPLYTA’s financial growth?
Generic competition post-patent expiration, market saturation, and regulatory delays.

---

References

[1] IQVIA. (2022). Global Markets for Psychiatry Drugs.
[2] GlobalData. (2022). Psychiatric Disorder Treatment Market Report.
[3] U.S. Food and Drug Administration. (2019-2022). Drug Approval and Labeling.